Q3 EPS Estimates for Organigram Lowered by Atb Cap Markets

Organigram Holdings Inc. (TSE:OGI) – Analysts at Atb Cap Markets lowered their Q3 2025 earnings per share (EPS) estimates for Organigram in a research report issued to clients and investors on Tuesday, February 11th. Atb Cap Markets analyst F. Gomes now forecasts that the company will post earnings per share of ($0.03) for the quarter, down from their previous forecast of ($0.02). The consensus estimate for Organigram’s current full-year earnings is $0.16 per share. Atb Cap Markets also issued estimates for Organigram’s Q4 2025 earnings at ($0.02) EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.00 EPS.

Other research analysts have also issued reports about the company. Canaccord Genuity Group cut their price objective on Organigram from C$3.60 to C$3.15 and set a “speculative buy” rating on the stock in a research report on Monday, December 9th. ATB Capital dropped their target price on Organigram from C$5.25 to C$3.50 in a research report on Tuesday, December 17th.

Organigram Trading Down 5.7 %

TSE:OGI opened at C$1.81 on Friday. The business’s 50-day moving average is C$2.24 and its two-hundred day moving average is C$2.31. The company has a debt-to-equity ratio of 3.07, a current ratio of 3.36 and a quick ratio of 2.62. Organigram has a 12 month low of C$1.80 and a 12 month high of C$3.95. The firm has a market capitalization of C$223.61 million, a PE ratio of -3.83, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13.

Organigram Company Profile

Organigram Inc is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.